Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages 1745-1753

  Paz Ares, Luis ^a   Hirsh, Vera ^b   Zhang, Li ^c   De Marinis, Filippo ^d   Yang, James Chih Hsin ^e   Wakelee, Heather A ^f   Seto, Takashi ^g   Wu, Yi Long ^h   Novello, Silvia ⁱ   Juhász, Erszébet ^j   Arén, Osvaldo ^k   Sun, Yan ^l   Schmelter, Thomas ^m   Ong, Teng Jin ⁿ   Penã, Carol ⁿ   Smit, Egbert F ^o   Mok, Tony S ^p  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^k International Center of Clinical Studies   (Chile)

^l PEKING UNION MEDICAL COLLEGE   (China)

^m BAYER PHARMA AG   (Germany)

ⁿ BAYER CORPORATION   (United States)

^o NETHERLANDS CANCER INSTITUTE   (Netherlands)

^p CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

EGFR mutation; KRAS mutation; Molecular targeted therapy; Non small cell lung cancer; Sorafenib

Indexed keywords

ANTIMETABOLITE; BIOLOGICAL MARKER; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; PACLITAXEL; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BACKACHE; BLEEDING; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM ISCHEMIA; CIRCULATING TUMOR CELL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DESQUAMATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUTATION; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84947943267     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000693     Document Type: Article

References (25)

1. Langer CJ, Mok T, Postmus PE. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev 2013;39:252-260.
2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Cell Lung Cancer. 2012;v1.2013. Available at: http://www.nccn. org/professionals/physician-gls/pdf/nscl.pdf. Accessed December 7, 2012.
3. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
4. Escudier B, Eisen T, Stadler WM, et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
5. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
6. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4274-4280.
7. Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol 2012;7:1574-1582.
8. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 2010;5:719-720.
9. Dingemans AM, Mellema WW, Groen HJ, et al. A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. Clin Cancer Res 2013;19:743-751.
10. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
12. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-1842.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
14. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci USA 2003;100:8817-8822.
15. Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 2005;102:16368-16373.
16. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011;17:7808-7815.
17. Kato T, Seto T, Nishio M, et al. Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationpositive nonsquamous non-small cell lung cancer (NSCLC): an openlabel randomized trial. J Clin Oncol 2014;32(15 Suppl):8005 (abstract).
18. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-538.
19. Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-1121.
20. Amann JM, Lee JW, Roder H, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 2010;5:169-178.
21. Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2010;69:337-340.
22. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 2012;7:1653-1660.
23. Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2013;79:59-64.
24. Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol. 2014;15:713-721.
25. Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat(® ) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer 2012;107:1820-1825.